Prognostic Role of CD68+ and CD163+ Tumour-Associated Macrophages and PD-L1 Expression in Oral Squamous Cell Carcinoma: A Meta-Analysis
dc.contributor.author | Chohan, MH | |
dc.contributor.author | Perry, M | |
dc.contributor.author | Laurance-Young, P | |
dc.contributor.author | Salih, VM | |
dc.contributor.author | Foey, AD | |
dc.date.accessioned | 2023-10-18T11:17:25Z | |
dc.date.available | 2023-10-18T11:17:25Z | |
dc.date.issued | 2023-06-16 | |
dc.identifier.issn | 0967-4845 | |
dc.identifier.issn | 2474-0896 | |
dc.identifier.other | ARTN 11065 | |
dc.identifier.uri | https://pearl.plymouth.ac.uk/handle/10026.1/21463 | |
dc.description.abstract |
Background: Oral squamous cell carcinoma (OSCC) is a common malignant cancer in humans. An abundance of tumour associated macrophages (TAMs) create an immunosuppressive tumour microenvironment (TME). TAM markers (CD163 and CD68) are seen to serve as prognostic factors in OSCC. PD-L1 has seen to widely modulate the TME but its prognostic significance remains controversial. The aim of this meta-analysis is to evaluate the prognostic role of CD163+, CD68+ TAMs and PD-L1 in OSCC patients. Methods: Searches in PubMed, Scopus and Web of Science were performed; 12 studies were included in this meta-analysis. Quality assessment of included studies was performed according to REMARK guidelines. Risk of bias across studies was investigated according to the rate of heterogeneity. Meta-analysis was performed to investigate the association of all three biomarkers with overall survival (OS). Results: High expression of CD163+ TAMs were associated with poor overall survival (HR = 2.64; 95% Cl: [1.65, 4.23]; p < 0.0001). Additionally, high stromal expression of CD163+ TAMs correlated with poor overall survival (HR = 3.56; 95% Cl: [2.33, 5.44]; p < 0.00001). Conversely, high CD68 and PD-L1 expression was not associated with overall survival (HR = 1.26; 95% Cl: [0.76, 2.07]; p = 0.37) (HR = 0.64; 95% Cl: [0.35, 1.18]; p = 0.15). Conclusion: In conclusion, our findings indicate CD163+ can provide prognostic utility in OSCC. However, our data suggests CD68+ TAMs were not associated with any prognostic relevance in OSCC patients, whereas PD-L1 expression may prove to be a differential prognostic marker dependent on tumour location and stage of progression. | |
dc.format.extent | 11065- | |
dc.format.medium | Electronic-eCollection | |
dc.language | eng | |
dc.publisher | Frontiers Media SA | |
dc.subject | macrophages | |
dc.subject | oral cancer | |
dc.subject | CD68 | |
dc.subject | PD-L1 | |
dc.subject | CD163 | |
dc.title | Prognostic Role of CD68+ and CD163+ Tumour-Associated Macrophages and PD-L1 Expression in Oral Squamous Cell Carcinoma: A Meta-Analysis | |
dc.type | journal-article | |
dc.type | Article | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37397243 | |
plymouth.volume | 80 | |
plymouth.publisher-url | http://dx.doi.org/10.3389/bjbs.2023.11065 | |
plymouth.publication-status | Published online | |
plymouth.journal | British Journal of Biomedical Science | |
dc.identifier.doi | 10.3389/bjbs.2023.11065 | |
plymouth.organisational-group | |Plymouth | |
plymouth.organisational-group | |Plymouth|Research Groups | |
plymouth.organisational-group | |Plymouth|Faculty of Health | |
plymouth.organisational-group | |Plymouth|Research Groups|Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | |Plymouth|Research Groups|Institute of Translational and Stratified Medicine (ITSMED)|CBR | |
plymouth.organisational-group | |Plymouth|REF 2021 Researchers by UoA | |
plymouth.organisational-group | |Plymouth|Users by role | |
plymouth.organisational-group | |Plymouth|Users by role|Academics | |
plymouth.organisational-group | |Plymouth|REF 2021 Researchers by UoA|UoA01 Clinical Medicine | |
plymouth.organisational-group | |Plymouth|REF 2021 Researchers by UoA|UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy | |
plymouth.organisational-group | |Plymouth|Faculty of Health|Peninsula Dental School | |
plymouth.organisational-group | |Plymouth|Faculty of Health|School of Biomedical Sciences | |
plymouth.organisational-group | |Plymouth|REF 2021 Researchers by UoA|UoA01 Clinical Medicine|UoA01 Clinical Medicine | |
dc.publisher.place | Switzerland | |
dcterms.dateAccepted | 2023-02-10 | |
dc.date.updated | 2023-10-18T11:17:20Z | |
dc.rights.embargodate | 2023-10-19 | |
dc.identifier.eissn | 2474-0896 | |
rioxxterms.versionofrecord | 10.3389/bjbs.2023.11065 |